• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Pathway(s) to a transparent future for clinical trial data

Pathway(s) to a transparent future for clinical trial data

February 21, 2014 By MassDevice Contributors Network

By Tom Ulrich

Ed. note: This is the second in a two-part series on making clinical trial data more transparent. Click here for part 1.

To grossly oversimplify, there are two kinds of people in the world: those who want to see data from clinical trials made widely and freely available, and those who would rather have the data restricted for privacy or business reasons. And as we noted in our last post, there are valid arguments to be made on both sides.

But is there a way to balance the benefits of openness and the safety of confidentiality?

Regulators, academics and companies are already working on several possible ways of answering that question. The European Medicines Agency, for instance, is moving forward with a new policy requiring full access to clinical trial data; how they will implement it is still under discussion. The U.S. Institute of Medicine has had a working group looking into possible frameworks for open data sharing for several months now. And Johnson & Johnson recently announced a new partnership with Yale University to open the doors to their vaults of raw trial data.

Vector

Others are weighing in as well. Harvard School of Public Health policy researcher Michelle Mello, JD, PhD, and her colleagues proposed in the New England Journal of Medicine four models for making clinical trial data available, aimed at encouraging openness while mitigating risks:

  1. Full availability of all data
  2. A query model where companies or a third-party intermediary retain control of data and investigators submit questions they’d like to have answered
  3. A sponsor-reviewed model where companies decide what data to make available and how
  4. A learned intermediary model where an independent third party would evaluate and oversee data requests and access

Ellis Neufeld, MD, PhD, who runs Boston Children’s Clinical and Translational Study Unit, notes that some companies have already adopted something akin to the sponsor-reviewed model described by Mello and her collaborators by inviting select scientists to take an unfettered look at data from particular trials.

"We have coming of age a generation that is used to sharing everything about themselves openly for everyone to see."

"Companies take this seriously, and want to learn from the data they have," he says. "I’ve collaborated with a couple of companies on review of their study safety and post-approval surveillance data, and they’ve been very forthcoming in allowing us to see and analyze all of the data they have. "

An issue of consent

Boston Children’s Informatics Program director Isaac Kohane, MD, PhD, for one, questions whether patient privacy is as much of a barrier as it’s been made out to be and wonders if the informed consent process might serve as both a barrier and a solution.

"Patients by and large are happy to share the data from the trials they participate in. It’s a question of being more robust about obtaining patient consent," he says. "Institutions need to say up front in their consents that the data will be shared, and say it in plain English."

He also proposes an answer that balances access with patient and corporate protection. "Every publication, clinical trial or patient cohort should have the data behind it available. But it has to be done responsibly, like with dbGap," referring to a publicly available NIH database of genotype/phenotype studies. Researchers can gain total access to dbGap data as long as they have a protocol that’s been approved by an institutional review board.

"That way," he says, "you commit researchers to good behavior and create a record of responsible use, rather than opening the data up to just anyone."

A moot point?

Kohane’s colleague, ClinicalTrials.gov founder Alexa McCray, PhD, agrees that more openness is needed, but also believes the question will sort itself out over the next 10 to 15 years, regardless of the solutions attempted today.

"We have coming of age a generation that is used to sharing everything about themselves openly for everyone to see," she says. "And patients with life-threatening disease and the families of children with chronic illness are often quite willing to make any information available for the purpose of solving disease.

"You’ll still need controls and regulatory oversight," she adds, "but just as data is becoming more available in other areas of science and of our lives, making trial data open is going to get a whole lot easier."

Filed Under: Big Data, Blog, News Well Tagged With: Boston Children's Hospital, Clinical Trials, Sunshine Laws, Vector Blog

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy